Artiva Biotherapeutics Inc. (ARTV)
NASDAQ: ARTVHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
ARTV stock chart
Technical analysisKey statistics
All statistics- Market cap
- $186.85M
- EPS (TTM)
- -$2.85
- Dividend yield
- None
- 52-week range
- 2.96 – 14.53
- Day range
- 3.77 – 3.93
- Volume / Avg
- 1.78M / 792.26K
- Beta
- —
- Shares outstanding
- 49.43M
52-week range
ARTV stock today
Artiva Biotherapeutics (ARTV) closed at $3.78 on Nov 20, down 1.31% (-$0.05), versus the S&P 500's 3.70% decline. Volume was 2.2x the average at 1.78M shares, a sign of unusually heavy trading. Shares are 74.0% below their 52-week high of $14.53, set on Apr 20, 2026 and 27.7% above the 52-week low of $2.96, near the bottom of the past year's range.
ARTV is down 11.9% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 20.8%. Artiva Biotherapeutics has posted a net loss over the last twelve months (EPS of -$2.85), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Artiva Biotherapeutics
Company profileArtiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. Its lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody -associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, and B-cell-non-Hodgkin lymphoma. The company also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 targeting chimeric antigen receptor (CAR)-NK cell product candidate for the treatment of various solid tumors, such as breast, gastric and esophageal, and bladder cancers; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate for the treatment of hematological malignancies.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Dr. Fred Aslan M.D.
- Headquarters
- San Diego, CA
- Employees
- 134
- IPO year
- 2024
- Website
- artivabio.com
Financial highlights
Full financialsIn fiscal 2025, Artiva Biotherapeutics generated $0 in revenue, down 100.0% from fiscal 2024, its first annual decline since 2024. Artiva Biotherapeutics reported a net loss of $83.9 million, compared with a loss of $65.4 million a year earlier. Diluted earnings per share came in at -$3.43.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Revenue | $0 | $251.00K | $33.49M |
| Growth | -100.00% | -99.25% | — |
| Net income | $-83.86M | $-65.37M | $-28.72M |
| EPS (diluted) | $-3.43 | $-5.81 | $-35.78 |
Analyst forecast
ForecastConsensus (6 analysts)
buy
Avg. price target
$20.75+448.94%
- Strong buy 0
- Buy 2
- Hold 4
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 11, 2026
- EPS actual vs est.
- $-0.56 vs $-0.54
- Surprise
- -3.70%
ARTV news
All ARTV news- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Artiva Biotherapeutics, Inc. - ARTVPR Newswire
- Weekly Buzz: ABBV, PFE Win FDA Nod; ARTV Slashes Jobs; DAVI, SGRY Strike DealsNasdaqAARD, ABBV, ARTV, AZN
- Artiva Biotherapeutics Announces Strategic Update and Discontinues Development of AlloNK®GlobeNewswire
Artiva Biotherapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| IKTInhibikase Therapeutics Inc. | 1.32 | +1.54% | $185.16M | vs ARTV |
| LCTXLineage Cell Therapeutics Inc. | 0.7719 | -5.87% | $195.26M | vs ARTV |
| CABACabaletta Bio Inc. | 0.9361 | -7.32% | $201.94M | vs ARTV |
| CGENCompugen Ltd. | 1.84 | -2.13% | $174.29M | vs ARTV |
| IPSCCentury Therapeutics Inc. | 1.17 | -11.74% | $211.56M | vs ARTV |
| ALLOAllogene Therapeutics Inc. | 0.6277 | -5.88% | $217.48M | vs ARTV |
| PALIPalisade Bio Inc. | 0.8399 | -9.24% | $150.74M | vs ARTV |
| SCTXScribe Therapeutics Inc. | 12.07 | -8.70% | $228.58M | vs ARTV |
Indexes, lists and sector
Artiva Biotherapeutics stock FAQ
What is Artiva Biotherapeutics's stock price today?
ARTV last traded at $3.78 as of Nov 20, 4:00 PM EST, down 1.31% on the day. Prices are delayed at least 15 minutes.
Who is Artiva Biotherapeutics's CEO?
Dr. Fred Aslan M.D. is the chief executive officer of Artiva Biotherapeutics Inc., which has about 134 employees.
What is the ARTV 52-week high?
The 52-week high for ARTV is $14.53 and the 52-week low is $2.96. The stock is currently 74.0% below its high.